METASTATIC OVARIAN CARCINOMA

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a spray directly into the abdomen, alongside standa…

This early-phase trial is testing a procedure called PIPAC, which turns liquid chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. It is for people with ovarian, uterine, appendix, colorectal, or stomach cancer that has spread to the li…

This early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…